NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 0.4% – Here’s What Happened

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price was down 0.4% during trading on Monday . The stock traded as low as $1.01 and last traded at $1.04. Approximately 102,508 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 124,001 shares. The stock had previously closed at $1.04.

Analyst Ratings Changes

Separately, Maxim Group restated a “hold” rating on shares of NeuroSense Therapeutics in a report on Monday, December 16th.

NeuroSense Therapeutics Trading Up 0.5 %

The business’s 50 day simple moving average is $1.12 and its two-hundred day simple moving average is $1.06. The firm has a market capitalization of $14.14 million, a P/E ratio of -1.22 and a beta of 1.30.

NeuroSense Therapeutics (NASDAQ:NRSN) last announced its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned about 0.24% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by hedge funds and other institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.